Share Price and Basic Stock Data
Last Updated: January 29, 2026, 10:18 am
| PEG Ratio | -5.45 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Camlin Fine Sciences Ltd operates within the specialty chemicals sector, focusing on producing a variety of chemical products. The company reported a market capitalization of ₹2,697 Cr and its stock is currently priced at ₹140. Over recent years, revenue trends have shown significant fluctuations. For instance, sales stood at ₹1,682 Cr for the fiscal year ending March 2023, marking a notable rise from ₹1,412 Cr in March 2022. However, the trailing twelve-month (TTM) sales figure of ₹1,752 Cr indicates a decline from the previous year. Quarterly sales figures also reflect this inconsistency, with September 2023 recording ₹406 Cr compared to ₹483 Cr in September 2022. This pattern suggests challenges in maintaining steady revenue growth, likely influenced by market dynamics and operational efficiencies. With a current operating profit margin (OPM) of 7%, there is potential for improvement in revenue generation strategies to align with sector averages.
Profitability and Efficiency Metrics
The profitability metrics of Camlin Fine Sciences reveal a concerning trend, particularly in net profit figures. The company reported a net profit of -₹33 Cr for the fiscal year ending March 2025, a significant deterioration from the profits recorded in previous years, such as ₹60 Cr in March 2022. Additionally, quarterly net profits turned negative in recent quarters, with -₹21 Cr in September 2023 and -₹116 Cr in September 2024. The operating profit margin has also declined, standing at 6% in September 2023 and 7% in the latest reporting. The return on equity (ROE) is currently at 15% and return on capital employed (ROCE) at 11%, both of which are relatively moderate compared to typical sector standards. The cash conversion cycle (CCC) of 143 days points to inefficiencies in managing working capital, indicating a potential area for operational improvement and cost control.
Balance Sheet Strength and Financial Ratios
Camlin Fine Sciences’ balance sheet reveals a total debt of ₹672 Cr against reserves of ₹871 Cr, resulting in a debt-to-equity ratio of 0.71. This ratio is relatively moderate, suggesting a balanced approach to leveraging, though it remains above the ideal threshold seen in the specialty chemicals sector. The interest coverage ratio (ICR) stands at 2.23x, indicating that the company can cover its interest expenses, albeit with limited cushion. Furthermore, the company’s current ratio of 1.40 signifies adequate short-term liquidity, while the quick ratio of 0.77 suggests potential challenges in meeting immediate obligations without relying on inventory liquidation. With a price-to-book value (P/BV) ratio of 3.51x, the stock valuation appears stretched compared to its book value of ₹47.81 per share, raising questions about market perceptions of future growth.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Camlin Fine Sciences is diverse, with promoters holding 48.03% of the company as of September 2023. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), accounted for 2.14% and 7.77% of the shareholding, respectively. This indicates a cautious approach from institutional players, especially given the recent decline in profitability. The number of shareholders has increased to 52,845, which may reflect growing retail interest, although the significant drop in FIIs from 10.18% in March 2023 to 1.61% in September 2023 raises concerns about external investor confidence. As the company navigates through financial challenges, the stability of the promoter’s stake may provide some reassurance to investors, but the overall declining trend in institutional interest could signal caution among more risk-averse investors.
Outlook, Risks, and Final Insight
The outlook for Camlin Fine Sciences appears mixed, with potential for recovery contingent on improving operational efficiencies and stabilizing revenue streams. Key risks include the sustained decline in profitability and increasing debt levels, which could hinder future growth initiatives. Additionally, fluctuations in raw material prices and competition within the specialty chemicals sector pose significant challenges. The company must focus on enhancing its cash flow management and operational performance to regain investor confidence. If the management successfully implements strategies to improve margins and control costs, a turnaround may be achievable. Conversely, if profitability continues to decline, the stock may face downward pressure, impacting investor sentiment and market positioning. Overall, the company’s future hinges on its ability to adapt to market conditions and operational challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 355 Cr. | 38.6 | 71.2/36.4 | 22.0 | 20.5 | 1.03 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 28.0 Cr. | 57.0 | 88.8/52.0 | 13.4 | 89.6 | 1.76 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 46.6 Cr. | 685 | 899/600 | 21.5 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,251 Cr. | 71.7 | 111/68.2 | 21.5 | 22.0 | 0.68 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 568 Cr. | 228 | 377/208 | 20.4 | 93.8 | 1.09 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,093.20 Cr | 656.92 | 58.13 | 182.97 | 0.47% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 483 | 388 | 427 | 420 | 406 | 386 | 377 | 381 | 417 | 431 | 437 | 424 | 460 |
| Expenses | 428 | 338 | 383 | 381 | 381 | 363 | 345 | 352 | 366 | 375 | 378 | 405 | 427 |
| Operating Profit | 55 | 50 | 44 | 39 | 25 | 23 | 31 | 29 | 52 | 56 | 59 | 19 | 33 |
| OPM % | 11% | 13% | 10% | 9% | 6% | 6% | 8% | 8% | 12% | 13% | 14% | 4% | 7% |
| Other Income | 3 | 10 | -8 | 6 | 2 | 2 | -96 | -15 | -151 | -8 | -17 | 3 | -4 |
| Interest | 18 | 12 | 10 | 10 | 20 | 14 | 16 | 23 | 26 | 34 | 16 | 16 | 19 |
| Depreciation | 14 | 16 | 18 | 19 | 19 | 21 | 13 | 15 | 17 | 14 | 18 | 17 | 19 |
| Profit before tax | 26 | 32 | 8 | 16 | -12 | -10 | -94 | -23 | -142 | -0 | 8 | -11 | -9 |
| Tax % | 61% | 28% | 59% | 25% | 72% | 47% | -13% | 48% | -18% | 2,164% | 99% | -0% | 65% |
| Net Profit | 10 | 23 | 3 | 12 | -21 | -14 | -82 | -35 | -116 | -7 | 0 | -11 | -15 |
| EPS in Rs | 0.74 | 1.36 | 0.52 | 0.83 | -1.03 | -0.63 | -4.11 | -1.81 | -5.33 | -0.22 | -0.04 | -0.53 | -0.76 |
Last Updated: January 2, 2026, 4:03 am
Below is a detailed analysis of the quarterly data for Camlin Fine Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 460.00 Cr.. The value appears strong and on an upward trend. It has increased from 424.00 Cr. (Jun 2025) to 460.00 Cr., marking an increase of 36.00 Cr..
- For Expenses, as of Sep 2025, the value is 427.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 405.00 Cr. (Jun 2025) to 427.00 Cr., marking an increase of 22.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Jun 2025) to 33.00 Cr., marking an increase of 14.00 Cr..
- For OPM %, as of Sep 2025, the value is 7.00%. The value appears strong and on an upward trend. It has increased from 4.00% (Jun 2025) to 7.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is -4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Jun 2025) to -4.00 Cr., marking a decrease of 7.00 Cr..
- For Interest, as of Sep 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -9.00 Cr.. The value appears strong and on an upward trend. It has increased from -11.00 Cr. (Jun 2025) to -9.00 Cr., marking an increase of 2.00 Cr..
- For Tax %, as of Sep 2025, the value is 65.00%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Jun 2025) to 65.00%, marking an increase of 65.00%.
- For Net Profit, as of Sep 2025, the value is -15.00 Cr.. The value appears to be declining and may need further review. It has decreased from -11.00 Cr. (Jun 2025) to -15.00 Cr., marking a decrease of 4.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.76. The value appears to be declining and may need further review. It has decreased from -0.53 (Jun 2025) to -0.76, marking a decrease of 0.23.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:31 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 558 | 489 | 534 | 721 | 892 | 1,049 | 1,187 | 1,412 | 1,682 | 1,454 | 1,667 | 1,752 |
| Expenses | 446 | 474 | 397 | 502 | 705 | 819 | 914 | 1,000 | 1,254 | 1,468 | 1,284 | 1,447 | 1,584 |
| Operating Profit | 63 | 84 | 92 | 32 | 16 | 73 | 135 | 187 | 158 | 213 | 170 | 220 | 167 |
| OPM % | 12% | 15% | 19% | 6% | 2% | 8% | 13% | 16% | 11% | 13% | 12% | 13% | 10% |
| Other Income | 9 | 9 | -1 | 14 | 12 | 14 | 3 | 5 | 33 | -4 | -142 | -203 | -26 |
| Interest | 25 | 24 | 24 | 31 | 32 | 41 | 48 | 42 | 41 | 66 | 70 | 111 | 85 |
| Depreciation | 12 | 16 | 17 | 22 | 27 | 29 | 33 | 44 | 56 | 63 | 56 | 64 | 69 |
| Profit before tax | 35 | 53 | 50 | -6 | -31 | 17 | 58 | 105 | 94 | 80 | -99 | -158 | -12 |
| Tax % | 18% | -4% | 28% | -26% | -22% | 82% | 49% | 38% | 36% | 50% | 6% | 0% | |
| Net Profit | 29 | 55 | 36 | -4 | -24 | 3 | 30 | 65 | 60 | 40 | -105 | -158 | -33 |
| EPS in Rs | 2.71 | 5.11 | 3.30 | -0.96 | -2.18 | 0.04 | 2.23 | 3.56 | 3.45 | 2.96 | -4.94 | -7.40 | -1.55 |
| Dividend Payout % | 12% | 8% | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 89.66% | -34.55% | -111.11% | -500.00% | 112.50% | 900.00% | 116.67% | -7.69% | -33.33% | -362.50% | -50.48% |
| Change in YoY Net Profit Growth (%) | 0.00% | -124.20% | -76.57% | -388.89% | 612.50% | 787.50% | -783.33% | -124.36% | -25.64% | -329.17% | 312.02% |
Camlin Fine Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 223% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 20% |
| 3 Years: | 19% |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -7% |
| Last Year: | -15% |
Last Updated: September 5, 2025, 1:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:30 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 10 | 10 | 12 | 12 | 12 | 13 | 16 | 16 | 17 | 19 | 19 |
| Reserves | 84 | 125 | 167 | 202 | 359 | 359 | 391 | 631 | 732 | 804 | 848 | 883 | 871 |
| Borrowings | 150 | 160 | 180 | 331 | 373 | 461 | 539 | 550 | 646 | 801 | 683 | 681 | 672 |
| Other Liabilities | 126 | 131 | 123 | 126 | 273 | 255 | 290 | 282 | 396 | 425 | 424 | 454 | 476 |
| Total Liabilities | 369 | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,037 | 2,037 |
| Fixed Assets | 83 | 106 | 140 | 201 | 278 | 272 | 306 | 584 | 601 | 858 | 816 | 704 | 700 |
| CWIP | 22 | 3 | 25 | 8 | 14 | 59 | 179 | 24 | 215 | 43 | 46 | 10 | 15 |
| Investments | 1 | 1 | 1 | 19 | 115 | 11 | 7 | 7 | 7 | 8 | 8 | 61 | 69 |
| Other Assets | 262 | 316 | 313 | 442 | 609 | 745 | 740 | 861 | 966 | 1,136 | 1,102 | 1,262 | 1,253 |
| Total Assets | 369 | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,037 | 2,037 |
Below is a detailed analysis of the balance sheet data for Camlin Fine Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 19.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 19.00 Cr..
- For Reserves, as of Sep 2025, the value is 871.00 Cr.. The value appears to be declining and may need further review. It has decreased from 883.00 Cr. (Mar 2025) to 871.00 Cr., marking a decrease of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 672.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 681.00 Cr. (Mar 2025) to 672.00 Cr., marking a decrease of 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 476.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 454.00 Cr. (Mar 2025) to 476.00 Cr., marking an increase of 22.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,037.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2,037.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 700.00 Cr.. The value appears to be declining and may need further review. It has decreased from 704.00 Cr. (Mar 2025) to 700.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 69.00 Cr., marking an increase of 8.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,253.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,262.00 Cr. (Mar 2025) to 1,253.00 Cr., marking a decrease of 9.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,037.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2,037.00 Cr..
Notably, the Reserves (871.00 Cr.) exceed the Borrowings (672.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -87.00 | -76.00 | -88.00 | -299.00 | -357.00 | -388.00 | -404.00 | -363.00 | -488.00 | -588.00 | -513.00 | -461.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 74 | 56 | 99 | 104 | 86 | 88 | 83 | 77 | 66 | 72 | 72 |
| Inventory Days | 145 | 184 | 311 | 277 | 207 | 219 | 204 | 200 | 178 | 255 | 256 | 233 |
| Days Payable | 132 | 144 | 171 | 110 | 154 | 127 | 119 | 99 | 112 | 129 | 154 | 162 |
| Cash Conversion Cycle | 85 | 114 | 196 | 266 | 157 | 178 | 173 | 184 | 143 | 192 | 174 | 143 |
| Working Capital Days | -4 | 12 | 1 | -6 | 19 | 43 | 22 | 55 | 40 | 42 | 51 | 35 |
| ROCE % | 28% | 28% | 24% | 5% | 0% | 7% | 11% | 13% | 10% | 10% | 8% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Commodities Fund | 4,624,431 | 2.01 | 68.63 | 2,957,188 | 2025-12-15 01:00:05 | 56.38% |
| Franklin India Opportunities Fund | 3,135,785 | 0.56 | 46.54 | 2,764,166 | 2025-12-15 01:00:05 | 13.44% |
| ICICI Prudential Multicap Fund | 2,665,909 | 0.24 | 39.56 | 1,802,309 | 2025-12-15 01:00:05 | 47.92% |
| Franklin India Multi Cap Fund | 1,581,171 | 0.46 | 23.46 | N/A | N/A | N/A |
| JM Small Cap Fund | 504,008 | 1.06 | 7.48 | N/A | N/A | N/A |
| JM Aggressive Hybrid Fund | 442,799 | 0.84 | 6.57 | 554,131 | 2026-01-25 00:29:23 | -20.09% |
| ICICI Prudential Retirement Fund - Pure Equity | 313,993 | 0.28 | 4.66 | N/A | N/A | N/A |
| ICICI Prudential MidCap Fund | 82,527 | 0.02 | 1.22 | N/A | N/A | N/A |
| ICICI Prudential Business Cycle Fund | 50,000 | 0 | 0.74 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -8.03 | -5.58 | 3.45 | 4.65 | 4.13 |
| Diluted EPS (Rs.) | -7.95 | -5.50 | 3.41 | 4.56 | 3.68 |
| Cash EPS (Rs.) | -5.04 | -1.57 | 6.51 | 7.42 | 8.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 47.81 | 48.29 | 48.18 | 43.26 | 47.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 47.81 | 50.97 | 52.25 | 48.52 | 55.67 |
| Revenue From Operations / Share (Rs.) | 88.68 | 96.32 | 107.04 | 89.95 | 93.11 |
| PBDIT / Share (Rs.) | 11.84 | 5.34 | 13.44 | 11.84 | 14.66 |
| PBIT / Share (Rs.) | 8.45 | 0.64 | 9.46 | 8.27 | 11.19 |
| PBT / Share (Rs.) | 2.61 | -5.93 | 5.12 | 5.99 | 8.24 |
| Net Profit / Share (Rs.) | -8.44 | -6.26 | 2.53 | 3.85 | 5.13 |
| NP After MI And SOA / Share (Rs.) | -7.40 | -5.54 | 3.32 | 3.87 | 4.00 |
| PBDIT Margin (%) | 13.35 | 5.54 | 12.55 | 13.16 | 15.74 |
| PBIT Margin (%) | 9.52 | 0.67 | 8.83 | 9.19 | 12.01 |
| PBT Margin (%) | 2.94 | -6.15 | 4.77 | 6.66 | 8.85 |
| Net Profit Margin (%) | -9.51 | -6.50 | 2.36 | 4.28 | 5.50 |
| NP After MI And SOA Margin (%) | -8.34 | -5.75 | 3.09 | 4.29 | 4.29 |
| Return on Networth / Equity (%) | -15.47 | -11.35 | 6.92 | 9.16 | 9.43 |
| Return on Capital Employeed (%) | 13.47 | 0.89 | 11.72 | 10.77 | 14.20 |
| Return On Assets (%) | -6.87 | -4.75 | 2.52 | 3.37 | 3.43 |
| Long Term Debt / Equity (X) | 0.29 | 0.40 | 0.54 | 0.58 | 0.50 |
| Total Debt / Equity (X) | 0.71 | 0.80 | 1.04 | 0.94 | 0.99 |
| Asset Turnover Ratio (%) | 0.83 | 0.80 | 0.46 | 0.48 | 0.52 |
| Current Ratio (X) | 1.40 | 1.37 | 1.37 | 1.50 | 1.66 |
| Quick Ratio (X) | 0.77 | 0.66 | 0.65 | 0.87 | 0.99 |
| Inventory Turnover Ratio (X) | 3.21 | 1.38 | 1.29 | 1.65 | 1.79 |
| Interest Coverage Ratio (X) | 2.23 | 1.48 | 3.61 | 5.20 | 4.98 |
| Interest Coverage Ratio (Post Tax) (X) | 1.59 | 0.08 | 1.85 | 2.69 | 2.74 |
| Enterprise Value (Cr.) | 3620.14 | 2050.95 | 2685.65 | 2687.50 | 2251.73 |
| EV / Net Operating Revenue (X) | 2.17 | 1.27 | 1.60 | 1.90 | 1.90 |
| EV / EBITDA (X) | 16.27 | 22.92 | 12.72 | 14.46 | 12.05 |
| MarketCap / Net Operating Revenue (X) | 1.89 | 0.92 | 1.19 | 1.55 | 1.50 |
| Price / BV (X) | 3.51 | 1.83 | 2.66 | 3.31 | 3.30 |
| Price / Net Operating Revenue (X) | 1.89 | 0.92 | 1.19 | 1.55 | 1.50 |
| EarningsYield | -0.04 | -0.06 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Camlin Fine Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -8.03. This value is below the healthy minimum of 5. It has decreased from -5.58 (Mar 24) to -8.03, marking a decrease of 2.45.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.95. This value is below the healthy minimum of 5. It has decreased from -5.50 (Mar 24) to -7.95, marking a decrease of 2.45.
- For Cash EPS (Rs.), as of Mar 25, the value is -5.04. This value is below the healthy minimum of 3. It has decreased from -1.57 (Mar 24) to -5.04, marking a decrease of 3.47.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.81. It has decreased from 48.29 (Mar 24) to 47.81, marking a decrease of 0.48.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.81. It has decreased from 50.97 (Mar 24) to 47.81, marking a decrease of 3.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 88.68. It has decreased from 96.32 (Mar 24) to 88.68, marking a decrease of 7.64.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.84. This value is within the healthy range. It has increased from 5.34 (Mar 24) to 11.84, marking an increase of 6.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.45. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 8.45, marking an increase of 7.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from -5.93 (Mar 24) to 2.61, marking an increase of 8.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -8.44. This value is below the healthy minimum of 2. It has decreased from -6.26 (Mar 24) to -8.44, marking a decrease of 2.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.40. This value is below the healthy minimum of 2. It has decreased from -5.54 (Mar 24) to -7.40, marking a decrease of 1.86.
- For PBDIT Margin (%), as of Mar 25, the value is 13.35. This value is within the healthy range. It has increased from 5.54 (Mar 24) to 13.35, marking an increase of 7.81.
- For PBIT Margin (%), as of Mar 25, the value is 9.52. This value is below the healthy minimum of 10. It has increased from 0.67 (Mar 24) to 9.52, marking an increase of 8.85.
- For PBT Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 10. It has increased from -6.15 (Mar 24) to 2.94, marking an increase of 9.09.
- For Net Profit Margin (%), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 5. It has decreased from -6.50 (Mar 24) to -9.51, marking a decrease of 3.01.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -8.34. This value is below the healthy minimum of 8. It has decreased from -5.75 (Mar 24) to -8.34, marking a decrease of 2.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is -15.47. This value is below the healthy minimum of 15. It has decreased from -11.35 (Mar 24) to -15.47, marking a decrease of 4.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.47. This value is within the healthy range. It has increased from 0.89 (Mar 24) to 13.47, marking an increase of 12.58.
- For Return On Assets (%), as of Mar 25, the value is -6.87. This value is below the healthy minimum of 5. It has decreased from -4.75 (Mar 24) to -6.87, marking a decrease of 2.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.29, marking a decrease of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has decreased from 0.80 (Mar 24) to 0.71, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has increased from 0.80 (Mar 24) to 0.83, marking an increase of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.37 (Mar 24) to 1.40, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.21. This value is below the healthy minimum of 4. It has increased from 1.38 (Mar 24) to 3.21, marking an increase of 1.83.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.23. This value is below the healthy minimum of 3. It has increased from 1.48 (Mar 24) to 2.23, marking an increase of 0.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.59. This value is below the healthy minimum of 3. It has increased from 0.08 (Mar 24) to 1.59, marking an increase of 1.51.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,620.14. It has increased from 2,050.95 (Mar 24) to 3,620.14, marking an increase of 1,569.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.17. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 2.17, marking an increase of 0.90.
- For EV / EBITDA (X), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 15. It has decreased from 22.92 (Mar 24) to 16.27, marking a decrease of 6.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.89, marking an increase of 0.97.
- For Price / BV (X), as of Mar 25, the value is 3.51. This value exceeds the healthy maximum of 3. It has increased from 1.83 (Mar 24) to 3.51, marking an increase of 1.68.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.89, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 24) to -0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Camlin Fine Sciences Ltd:
- Net Profit Margin: -9.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.47% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -15.47% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.59
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 164 (Industry average Stock P/E: 58.13)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -9.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Floor 2 to 5, In GS Point, Mumbai Maharashtra 400098 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ashish Dandekar | Chairman & Managing Director |
| Mr. Nirmal Momaya | Managing Director |
| Mr. Arjun Dukane | Executive Director -Technical |
| Mr. Joseph Conrad D'souza | Independent Director |
| Ms. Anagha Dandekar | Non Exe.Non Ind.Director |
| Mr. Harsha Raghavan | Non Exe.Non Ind.Director |
| Mr. Jens Van Nieuwenborgh | Non Exe.Non Ind.Director |
| Mr. Mahabaleshwar Palekar | Independent Director |
| Mr. Pradip Kanakia | Independent Director |
| Mr. Amol Shah | Independent Director |
| Ms. Radhika Dudhat | Independent Director |
| Mr. Abeezar Faizullabhoy | Independent Director |
FAQ
What is the intrinsic value of Camlin Fine Sciences Ltd?
Camlin Fine Sciences Ltd's intrinsic value (as of 29 January 2026) is ₹663.52 which is 380.81% higher the current market price of ₹138.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,644 Cr. market cap, FY2025-2026 high/low of ₹335/122, reserves of ₹871 Cr, and liabilities of ₹2,037 Cr.
What is the Market Cap of Camlin Fine Sciences Ltd?
The Market Cap of Camlin Fine Sciences Ltd is 2,644 Cr..
What is the current Stock Price of Camlin Fine Sciences Ltd as on 29 January 2026?
The current stock price of Camlin Fine Sciences Ltd as on 29 January 2026 is ₹138.
What is the High / Low of Camlin Fine Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Camlin Fine Sciences Ltd stocks is ₹335/122.
What is the Stock P/E of Camlin Fine Sciences Ltd?
The Stock P/E of Camlin Fine Sciences Ltd is 164.
What is the Book Value of Camlin Fine Sciences Ltd?
The Book Value of Camlin Fine Sciences Ltd is 47.3.
What is the Dividend Yield of Camlin Fine Sciences Ltd?
The Dividend Yield of Camlin Fine Sciences Ltd is 0.00 %.
What is the ROCE of Camlin Fine Sciences Ltd?
The ROCE of Camlin Fine Sciences Ltd is 11.0 %.
What is the ROE of Camlin Fine Sciences Ltd?
The ROE of Camlin Fine Sciences Ltd is 15.0 %.
What is the Face Value of Camlin Fine Sciences Ltd?
The Face Value of Camlin Fine Sciences Ltd is 1.00.